{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-194715","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.320426+00:00","generated_at":"2026-06-13T02:13:52.874615+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Alnylam partners with Roche on zilebesiran; receives $310M upfront, up to $2.5B milestones","bullets":["Upfront cash payment of $310 million; potential total deal value up to $2.8 billion including development, regulatory, and sales milestones.","Alnylam and Roche to co-develop and co-commercialize zilebesiran in US (50/50 profit share); Roche gets exclusive ex-US rights with low double-digit royalties.","Alnylam leads joint clinical development plan including cardiovascular outcomes trial; development costs split 40% Alnylam, 60% Roche.","Zilebesiran is an investigational RNAi therapeutic for hypertension, currently in Phase 2; Phase 1 showed durable blood pressure reduction up to 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-194715","json":"https://secwatch.observer/filing/0001193125-23-194715.json","markdown":"https://secwatch.observer/filing/0001193125-23-194715.md","text":"https://secwatch.observer/filing/0001193125-23-194715.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/0001193125-23-194715-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/d448801d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T02:13:52.874615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a12b8f539978a4dc08d134bf6cb616b2d8eaa953","claim":"ALNYLAM PHARMACEUTICALS, INC. entered into Collaboration and License Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. valued at $310 million (effective 2023-07-21).","evidence_excerpt":"On July 21, 2023 (the “ Effective Date ”), Alnylam Pharmaceuticals, Inc. (the “ Company ”), entered into a Collaboration and License Agreement (the “ Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Genentech, Inc. (“ Genentech ,” each of Roche Basel and Genentech, individually and collectively, “ Roche ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523194715/0001193125-23-194715-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"F. Hoffmann-La Roche Ltd. and Genentech, Inc."},{"label":"Value","value":"$310 million"},{"label":"Effective","value":"2023-07-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}